These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28492659)

  • 1. Ensemble clustering of phosphoproteomic data identifies differences in protein interactions and cell-cell junction integrity of HER2-overexpressing cells.
    Schaberg KE; Shirure VS; Worley EA; George SC; Naegle KM
    Integr Biol (Camb); 2017 Jun; 9(6):539-547. PubMed ID: 28492659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoproteomic analysis of Her2/neu signaling and inhibition.
    Bose R; Molina H; Patterson AS; Bitok JK; Periaswamy B; Bader JS; Pandey A; Cole PA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9773-8. PubMed ID: 16785428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR signaling to p120-catenin through phosphorylation at Y228.
    Mariner DJ; Davis MA; Reynolds AB
    J Cell Sci; 2004 Mar; 117(Pt 8):1339-50. PubMed ID: 14996911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion.
    Larive RM; Urbach S; Poncet J; Jouin P; Mascré G; Sahuquet A; Mangeat PH; Coopman PJ; Bettache N
    Oncogene; 2009 Jun; 28(24):2337-47. PubMed ID: 19421152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
    Lu Y; Zi X; Zhao Y; Pollak M
    Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of HER2-induced endothelial cell retraction.
    Carter WB; Niu G; Ward MD; Small G; Hahn JE; Muffly BJ
    Ann Surg Oncol; 2007 Oct; 14(10):2971-8. PubMed ID: 17593333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
    Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
    Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
    Pham TND; Perez White BE; Zhao H; Mortazavi F; Tonetti DA
    BMC Cancer; 2017 Dec; 17(1):832. PubMed ID: 29216867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
    Hamyeh M; Bernex F; Larive RM; Naldi A; Urbach S; Simony-Lafontaine J; Puech C; Bakhache W; Solassol J; Coopman PJ; Hendriks WJAJ; Freiss G
    Theranostics; 2020; 10(3):1016-1032. PubMed ID: 31938048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells.
    Cheng JC; Qiu X; Chang HM; Leung PC
    Biochem Biophys Res Commun; 2013 Apr; 434(1):81-6. PubMed ID: 23542467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Wu Y; Ginther C; Kim J; Mosher N; Chung S; Slamon D; Vadgama JV
    Mol Cancer Res; 2012 Dec; 10(12):1597-606. PubMed ID: 23071104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin surface levels in epithelial growth factor-stimulated cells depend on adherens junction protein shrew-1.
    Gross JC; Schreiner A; Engels K; Starzinski-Powitz A
    Mol Biol Cell; 2009 Aug; 20(15):3598-607. PubMed ID: 19515834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
    Wang SE; Wu FY; Shin I; Qu S; Arteaga CL
    Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmentalization in membrane rafts defines a pool of N-cadherin associated with catenins and not engaged in cell-cell junctions in melanoma cells.
    Rossier-Pansier L; Baruthio F; Rüegg C; Mariotti A
    J Cell Biochem; 2008 Feb; 103(3):957-71. PubMed ID: 17668445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.